Posts Tagged ‘GLP-1 agonists’

At the opening of the ANZMOSS (Australian and New Zealand Metabolic and Obesity Surgery Society) meeting today, we had the unique privilege of helping people peer into the future of obesity care. Endocrine surgeon Juan Pablo Pantoja presented a view of the future of bariatric surgery in the era of a medical frenzy. The frenzy, […]

At ENDO2025 Saturday, we got a fresh view of the future that lies ahead for medical and surgical obesity care. In a sharp contrast to either/or constructs that pit medical and surgical care as rivals, endocrinology fellow Angela Rao presented data pointing to complementary roles for medical and surgical obesity care. Analyzing data from 846 […]

A dramatic race is progressing quietly and out of view for most of us. It is the race toward better therapy for the liver disease doctors know as MASH (metabolic associated steatohepatitis), which has close ties to obesity. And likewise because of advances in obesity science, progress in treating MASH is advancing with blinding speed […]

On the closing day of the ADA Scientific Sessions in Chicago, we got a good look at two remarkable new obesity drugs. Both of them have potential to bring important advances. Both of them need more work before they will be ready to go to FDA for approval. This was a rare treat. Bimagrumab The […]

While much of the public has focused on the remarkable effects of GLP-1 agonists for many people living with obesity, an even more remarkable story has largely escaped notice. In March, FDA approved the first ever treatment for Prader-Willi syndrome. This drug, an extended-release form of diazoxide choline, is transforming the lives of families of […]

As the upcoming Scientific Sessions for the American Diabetes Association draws closer, the drumbeat for amycretin as a promising new therapy for obesity is growing louder. At the meeting, Novo Nordisk plans to present two different studies to strengthen the case for this novel dual agonist. It targets both GLP-1 and amylin receptors. Then yesterday […]

Thoughtful reporting by Jackie Snow in the New York Times prompts us to wonder about the possibility of a “contagion effect” from GLP-1s in families. When a parent receives highly effective treatment for obesity, what might the effect be on other family members? Of course, any answers to this question come from anecdotal observations. They […]

Honestly, we cannot figure out why this basic fact of obesity treatment seems so hard for so many people to grasp. New, advanced medicines for obesity don’t work well when a person doesn’t take them. A new study in Obesity drives this point home. Hamlet Gasoyan and colleagues found that discontinuations and sub-optimal dosing of […]

It is fascinating. Nutrition 2025 concluded yesterday in Orlando and even though the conference is all about nutrition research, an intense interest in the interaction of GLP-1 medicines with nutrition was a theme in the meeting from its very start all the way to the end. At the end, with two distinguished obesity researchers, Randy […]

This weekend, as Nutrition 2025 opens, four diverse professional groups announced a noteworthy collaboration. These groups came together to publish a clinical advisory on nutrition priorities that support GLP-1 therapy for obesity. The groups are the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and the […]